An Overview of the NCCN and ASCO Guidelines on Cancer-Associated Venous Thromboembolism

REFERENCES

• Trousseau A., Bazire P. V., Cormack J. R. Lectures on Clinical Medicine, Delivered at the Hotel-Dieu, Paris. The New Sydenham Society, London 1868
   Google Scholar
• Heit J. A., Silverstein M. D., Mohr D. N., Petterson T. M., O'Fallon W. M., Melton L. J., 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med Mar 27, 2000; 160(6)809–815
   PubMed Web of Science ®Google Scholar
• Blom J. W., Doggen C. J., Osanto S., Rosendaal F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA Feb 9, 2005; 293(6)715–722
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Fisher R. I., Kuderer N. M., Lyman G. H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol Jan 20, 2006; 24(3)484–490
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Kuderer N. M., Lyman G. H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost Mar, 2007; 5(3)632–634
   PubMed Web of Science ®Google Scholar
• Stein P. D., Beemath A., Olson R. E. Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. Am J Cardiol Jun 15, 2005; 95(12)1525–1526
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Levine M., Pinedo H. M., Wolff R., Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003; 8(4)381–388
   PubMed Web of Science ®Google Scholar
• Tapson V. F., Decousus H., Pini M., et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest Sep, 2007; 132(3)936–945
   PubMed Web of Science ®Google Scholar
• Tapson V. F., Hyers T. M., Waldo A. L., et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med Jul 11, 2005; 165(13)1458–1464
   PubMed Web of Science ®Google Scholar
• Hylek E. M., Regan S., Henault L. E., et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med Mar 10, 2003; 163(5)621–627
   PubMed Web of Science ®Google Scholar
• Jaff M. R., Goldhaber S. Z., Tapson V. F. High utilization rate of vena cava filters in deep vein thrombosis. Thromb Haemost Jun, 2005; 93(6)1117–1119
   PubMed Web of Science ®Google Scholar
• Wagman L. D., Baird M. F., Bennett C. L., et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw Oct, 2006; 4(9)838–869
   PubMedGoogle Scholar
• Lyman G. H., Khorana A. A., Falanga A., et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol Dec 1, 2007; 25(34)5490–5505
   PubMed Web of Science ®Google Scholar
• Samama M. M., Cohen A. T., Darmon J. Y., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med Sep 9, 1999; 341(11)793–800
   PubMed Web of Science ®Google Scholar
• Leizorovicz A., Cohen A. T., Turpie A. G., et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation Aug 17, 2004; 110(7)874–879
   PubMed Web of Science ®Google Scholar
• Cohen A. T., Davidson B. L., Gallus A. S., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo-controlled trial. BMJ Feb 11, 2006; 332(7537)325–329
   PubMed Web of Science ®Google Scholar
• Mismetti P., Laporte-Simitsidis S., Tardy B., et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost Jan, 2000; 83(1)14–19
   PubMed Web of Science ®Google Scholar
• King C. S., Holley A. B., Jackson J. L., Shorr A. F., Moores L. K. Twice vs. three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a meta-analysis. Chest Feb, 2007; 131(2)507–516
   PubMed Web of Science ®Google Scholar
• Comerota A. J., Katz M. L., White J. V. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail?. Am J Surg Sep, 1992; 164(3)265–268
   PubMed Web of Science ®Google Scholar
• Cornwell E. E., 3rd, Chang D., Velmahos G., et al. Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg May, 2002; 68(5)470–473
   PubMed Web of Science ®Google Scholar
• Roderick P., Ferris G., Wilson K., et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess Dec, 2005; 9(49)1–78, (iii, iv, ix, x)
   Web of Science ®Google Scholar
• Urbankova J., Quiroz R., Kucher N., Goldhaber S. Z. Intermittent pneumatic compression and deep vein thrombosis prevention. A meta-analysis in postoperative patients. Thromb Haemost Dec, 2005; 94(6)1181–1185
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Williamson R. C. Thromboprophylaxis in the cancer patient. Haemostasis 1998; 28(Suppl. 3)61–65
   PubMedGoogle Scholar
• Agnelli G., Bolis G., Capussotti L., et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg Jan, 2006; 243(1)89–95
   PubMed Web of Science ®Google Scholar
• Mismetti P., Laporte S., Darmon J. Y., Buchmuller A., Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg Jul, 2001; 88(7)913–930
   PubMed Web of Science ®Google Scholar
• ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg Aug, 1997; 84(8)1099–1103
   PubMed Web of Science ®Google Scholar
• Turpie A. G., Bauer K. A., Caprini J. A., et al. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost Sep, 2007; 5(9)1854–1861
   PubMed Web of Science ®Google Scholar
• Bergqvist D., Agnelli G., Cohen A. T., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med Mar 28, 2002; 346(13)975–980
   PubMed Web of Science ®Google Scholar
• Rasmussen M. S., Jorgensen L. N., Wille-Jorgensen P., et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost Nov, 2006; 4(11)2384–2390
   PubMed Web of Science ®Google Scholar
• Heit J. A., Melton L. J., 3rd, Lohse C. M., et al. Incidence of venous thromboembolism in hospitalized patients vs. community residents. Mayo Clin Proc Nov, 2001; 76(11)1102–1110
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Lyman G. H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer Dec 15, 2005; 104(12)2822–2829
   PubMed Web of Science ®Google Scholar
• Bennett C. L., Angelotta C., Yarnold P. R., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA Dec 6, 2006; 296(21)2558–2560
   PubMed Web of Science ®Google Scholar
• Levine M., Hirsh J., Gent M., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet Apr 9, 1994; 343(8902)886–889
   PubMed Web of Science ®Google Scholar
• Rajan R., Gafni A., Levine M., Hirsh J., Gent M. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol Jan, 1995; 13(1)42–46
   PubMed Web of Science ®Google Scholar
• Haas S. K., Kakkar A. K., Kemkes-Matthes B., et al. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer—results of the TOPIC studies. J Thromb Haemost 2005; 3(Suppl. 1), Abstract OR059
   Google Scholar
• Khorana A. A., Kuderer N. M., Culakova E., Lyman G. H., Francis C. W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood May 15, 2008; 111(10)4902–4907
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Levine M. N., Butler G., et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol Mar 20, 2006; 24(9)1404–1408
   PubMed Web of Science ®Google Scholar
• Verso M., Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol Oct 1, 2003; 21(19)3665–3675
   PubMed Web of Science ®Google Scholar
• Bern M. M., Lokich J. J., Wallach S. R., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med Mar 15, 1990; 112(6)423–428
   PubMed Web of Science ®Google Scholar
• Monreal M., Alastrue A., Rull M., et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices–prophylaxis with a low molecular weight heparin (fragmin). Thromb Haemost Feb, 1996; 75(2)251–253
   PubMed Web of Science ®Google Scholar
• Couban S., Goodyear M., Burnell M., et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol Jun 20, 2005; 23(18)4063–4069
   PubMed Web of Science ®Google Scholar
• Verso M., Agnelli G., Bertoglio S., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol Jun 20, 2005; 23(18)4057–4062
   PubMed Web of Science ®Google Scholar
• Niers T. M., Di Nisio M., Klerk C. P., Baarslag H. J., Buller H. R., Biemond B. J. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost Sep, 2007; 5(9)1878–1882
   PubMed Web of Science ®Google Scholar
• Wells P. S., Anderson D. R., Rodger M., et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med Sep 25, 2003; 349(13)1227–1235
   PubMed Web of Science ®Google Scholar
• Kearon C., Ginsberg J. S., Douketis J., et al. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med Jun 6, 2006; 144(11)812–821
   PubMed Web of Science ®Google Scholar
• van Belle A., Buller H. R., Huisman M. V., et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA Jan 11, 2006; 295(2)172–179
   PubMed Web of Science ®Google Scholar
• Carrier M., Lee A. Y., Bates S. M., Anderson D. R., Wells P. S. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients. Thromb Res Jun 14, 2008; 123(1)177–183
   PubMed Web of Science ®Google Scholar
• Sohne M., Kruip M. J., Nijkeuter M., et al. Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost May, 2006; 4(5)1042–1046
   PubMed Web of Science ®Google Scholar
• Kearon C., Julian J. A., Newman T. E., Ginsberg J. S. Noninvasive diagnosis of deep venous thrombosis. McMaster diagnostic imaging practice guidelines initiative. Ann Intern Med Apr 15, 1998; 128(8)663–677
   PubMed Web of Science ®Google Scholar
• Stevens S. M., Elliott C. G., Chan K. J., Egger M. J., Ahmed K. M. Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. Ann Intern Med Jun 15, 2004; 140(12)985–991
   PubMed Web of Science ®Google Scholar
• Baarslag H. J., van Beek E. J., Koopman M. M., Reekers J. A. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med Jun 18, 2002; 136(12)865–872
   PubMed Web of Science ®Google Scholar
• Rosovsky R. P., Kuter D. J. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. Hematol Oncol Clin North Am Feb, 2005; 19(1)183, 202, vii
   PubMed Web of Science ®Google Scholar
• Anderson D. R., Kahn S. R., Rodger M. A., et al. Computed tomographic pulmonary angiography vs. ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA Dec 19, 2007; 298(23)2743–2753
   PubMed Web of Science ®Google Scholar
• Tillie-Leblond I., Mastora I., Radenne F., et al. Risk of pulmonary embolism after a negative spiral CT angiogram in patients with pulmonary disease: 1-year clinical follow-up study. Radiology May, 2002; 223(2)461–467
   PubMed Web of Science ®Google Scholar
• Stein P. D., Woodard P. K., Weg J. G., et al. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II investigators. Radiology Jan, 2007; 242(1)15–21
   PubMed Web of Science ®Google Scholar
• Prandoni P., Lensing A. W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood Nov 15, 2002; 100(10)3484–3488
   PubMed Web of Science ®Google Scholar
• Hutten B. A., Prins M. H., Gent M., Ginsberg J., Tijssen J. G., Buller H. R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol Sep, 2000; 18(17)3078–3083
   PubMed Web of Science ®Google Scholar
• Palareti G., Legnani C., Lee A., et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost Nov, 2000; 84(5)805–810
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Levine M. N., Baker R. I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med Jul 10, 2003; 349(2)146–153
   PubMed Web of Science ®Google Scholar
• Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med Aug 12–26, 2002; 162(15)1729–1735
   PubMed Web of Science ®Google Scholar
• Hull R. D., Pineo G. F., Brant R. F., et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med Dec, 2006; 119(12)1062–1072
   PubMed Web of Science ®Google Scholar
• Deitcher S. R., Kessler C. M., Merli G., et al. Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost Oct, 2006; 12(4)389–396
   PubMed Web of Science ®Google Scholar
• Lim W., Dentali F., Eikelboom J. W., Crowther M. A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med May 2, 2006; 144(9)673–684
   PubMed Web of Science ®Google Scholar
• Kim H. S., Young M. J., Narayan A. K., Hong K., Liddell R. P., Streiff M. B. A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters. J Vasc Interv Radiol Mar, 2008; 19(3)393–399
   PubMed Web of Science ®Google Scholar
• Van Ha T. G., Chien A. S., Funaki B. S., et al. Use of retrievable compared to permanent inferior vena cava filters: a single-institution experience. Cardiovasc Intervent Radiol Mar–Apr, 2008; 31(2)308–315
   PubMed Web of Science ®Google Scholar
• Comerota A. J., Aldridge S. C. Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg Aug, 1993; 36(4)359–364
   PubMed Web of Science ®Google Scholar
• Mewissen M. W., Seabrook G. R., Meissner M. H., Cynamon J., Labropoulos N., Haughton S. H. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology Apr, 1999; 211(1)39–49
   PubMed Web of Science ®Google Scholar
• Kim H. S., Preece S. R., Black J. H., Pham L. D., Streiff M. B. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg Feb, 2008; 47(2)388–394
   PubMed Web of Science ®Google Scholar
• Munoz F. J., Mismetti P., Poggio R., et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE registry. Chest Jan, 2008; 133(1)143–148
   PubMed Web of Science ®Google Scholar
• Kovacs M. J., Kahn S. R., Rodger M., et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (Dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (the catheter study). J Thromb Haemost Aug, 2007; 5(8)1650–1653
   PubMed Web of Science ®Google Scholar
• Linenberger M. L. Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw Oct, 2006; 4(9)889–901
   PubMedGoogle Scholar
• Lagerstedt C. I., Olsson C. G., Fagher B. O., Oqvist B. W., Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet Sep 7, 1985; 2(8454)515–518
   PubMed Web of Science ®Google Scholar
• Moser K. M., LeMoine J. R. Is embolic risk conditioned by location of deep venous thrombosis?. Ann Intern Med Apr, 1981; 94: 439–444, (4, pt 1)
   PubMed Web of Science ®Google Scholar
• Pinede L., Ninet J., Duhaut P., et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation May 22, 2001; 103(20)2453–2460
   PubMed Web of Science ®Google Scholar
• Ageno W., Grimwood R., Limbiati S., Dentali F., Steidl L., Wells P. S. Home-treatment of deep vein thrombosis in patients with cancer. Haematologica Feb, 2005; 90(2)220–224
   PubMedGoogle Scholar
• Dager W. E., King J. H., Branch J. M., et al. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. Ann Pharmacother Jul–Aug, 2005; 39(7–8)1182–1187
   PubMed Web of Science ®Google Scholar
• Siragusa S., Arcara C., Malato A., et al. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol May, 2005; 16(Suppl. 4)iv136–iv139
   PubMedGoogle Scholar
• Kovacs M. J., Anderson D., Morrow B., Gray L., Touchie D., Wells P. S. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost Feb, 2000; 83(2)209–211
   PubMed Web of Science ®Google Scholar
• Goldhaber S. Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER). Lancet Apr 24, 1999; 353(9162)1386–1389
   PubMed Web of Science ®Google Scholar
• Wicki J., Perrier A., Perneger T. V., Bounameaux H., Junod A. F. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost Oct, 2000; 84(4)548–552
   PubMed Web of Science ®Google Scholar
• Kucher N., Rossi E., De Rosa M., Goldhaber S. Z. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm hg or higher. Arch Intern Med Aug 8–22, 2005; 165(15)1777–1781
   PubMed Web of Science ®Google Scholar
• Schoepf U. J., Kucher N., Kipfmueller F., Quiroz R., Costello P., Goldhaber S. Z. Right ventricular enlargement on chest-computed tomography: a predictor of early death in acute pulmonary embolism. Circulation Nov 16, 2004; 110(20)3276–3280
   PubMed Web of Science ®Google Scholar
• Konstantinides S., Geibel A., Heusel G., Heinrich F., Kasper W. Management strategies and prognosis of pulmonary embolism-3 trial investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med Oct 10, 2002; 347(15)1143–1150
   PubMed Web of Science ®Google Scholar
• Marchiori A., Mosena L., Prandoni P. Superficial vein thrombosis: risk factors, diagnosis, and treatment. Semin Thromb Hemost Oct, 2006; 32(7)737–743
   PubMed Web of Science ®Google Scholar
• Di Nisio M., Wichers I. M., Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2007, (Apr 18), (2):, CD004982
   Google Scholar
• Marchiori A., Verlato F., Sabbion P., et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica May, 2002; 87(5)523–527
   PubMedGoogle Scholar
• Prandoni P., Tormene D., Pesavento R., Vesalio Investigators Group. High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trial. J Thromb Haemost Jun, 2005; 3(6)1152–1157
   PubMed Web of Science ®Google Scholar
• Enoxaparin Study Group. Superficial thrombophlebitis Treatment. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med Jul 28, 2003; 163(14)1657–1663
   PubMed Web of Science ®Google Scholar
• Brose K. M., Lee A. Y. Cancer-associated thrombosis: prevention and treatment. Curr Oncol Jan, 2008; 15(Suppl. 1)S58–S67
   PubMedGoogle Scholar
• Nash G. F., Walsh D. C., Kakkar A. K. The role of the coagulation system in tumour angiogenesis. Lancet Oncol Oct, 2001; 2(10)608–613
   PubMed Web of Science ®Google Scholar
• Zacharski L. R., Henderson W. G., Rickles F. R., et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans administration study no. 75. JAMA Feb 27, 1981; 245(8)831–835
   PubMed Web of Science ®Google Scholar
• Aisner J., Goutsou M., Maurer L. H., et al. Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a cancer and leukemia group B pilot study. J Clin Oncol Aug, 1992; 10(8)1230–1236
   PubMed Web of Science ®Google Scholar
• Maurer L. H., Herndon J. E., 2nd, Hollis D. R., et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a cancer and leukemia group B study. J Clin Oncol Nov, 1997; 15(11)3378–3387
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Levine M. N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol May 15, 2004; 22(10)1944–1948
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Rickles F. R., Julian J. A., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol Apr 1, 2005; 23(10)2123–2129
   PubMed Web of Science ®Google Scholar
• Klerk C. P., Smorenburg S. M., Otten H. M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol Apr 1, 2005; 23(10)2130–2135
   PubMed Web of Science ®Google Scholar
• Altinbas M., Coskun H. S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost Aug, 2004; 2(8)1266–1271
   PubMed Web of Science ®Google Scholar
• Kuderer N. M., Khorana A. A., Lyman G. H., Francis C. W. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer Sep 1, 2007; 110(5)1149–1161
   PubMed Web of Science ®Google Scholar